Wataru Tajima is new chief of Shimadzu Analytical (India)
Wataru Tajima has taken charge of office as deputy-managing director, Shimadzu Analytical (India) Pvt Ltd (covering India, Pakistan, Bangladesh, Nepal, Sri Lanka), from Shigenori Nada, managing director, who moved back due to ill health. Tajima has been with Shimadzu Corporation for over 17 years and worked at different sections/ divisions.
A science graduate from Waseda University, Japan, Tajima joined Shimadzu Corporation in 1990 at the ferrous and non-ferrous instrumentation section. Immediately, he moved to India to set up the steel plant at Visakhapatnam. Having stayed for three years in India, he moved to Singapore. From 2002, he started handling the analytical section at Shimadzu. He has been instrumental in setting up the present office and customer support center for Shimadzu Corporation in India. Shimadzu India was registered in 2005 and its office was opened in Mumbai in April 2006.
Dr Himadri Sen joins Ranbaxy as President R&D
Ranbaxy Laboratories has appointed Dr Himadri Sen as its president, R&D (Generics & NDDS).
Malvinder Singh, CEO and MD, Ranbaxy, said, "We are very pleased to renew our close association with Dr Sen. His appointment adds significant weight to the substantial research and development effort currently underway at Ranbaxy while underscoring our commitment to this strategic function that is core to India's future success in the global pharmaceutical industry."
Dr Sen has worked with leading Indian and global pharmaceutical companies in the areas of pharmaceutical research, technology development and transfer, plant support activities and regulatory affairs. He has been associated in various capacities with organizations like the Manchester Area Health Authority, UK, St Mary's Hospital and International Development Laboratories, UK, Imperial Chemical Industries, UK, E.R. Squibb and Sons Ltd, UK, Lupin and Ranbaxy Labs, India.
Dr Sen is credited with the development and approval of more than 70 INDs, NDAs and ANDAs for the US and EU. He has been responsible for development and commercialization of 60 OCRS, including the licensing of two products to companies in the US.